Acute leukaemia, Lymphoma, Multiple myeloma, Solid tumours
Adult: As a single agent: 60-90 mg/m2 every 3-4 wk. May divide dose over 2-3 days if desired. May admin as an inj over 3-5 minutes or as an infusion over up to 30 minutes. Max (total cumulative dose limit): 0.9-1 g/m2. For palliative care: 12.5-25 mg/m2 once wkly.
Adjuvant treatment of axillary-node positive breast cancer
Adult: Recommended starting dose: 100-120 mg/m2. Dose may be given as a single dose on day 1 or in 2 equally-divided doses on days 1 and 8 of each 28-day cycle. Repeat for 6 cycles. Lower starting doses may be considered in patients with pre-existing bone marrow depression or in the presence of neoplastic bone marrow infiltration.
Local treatment of bladder carcinoma
Adult: As 0.1% solution (in normal saline or sterile water): 50 mg weekly for 8 weeks; may reduce to 30 mg in 50 mL weekly, if chemical cystitis develops. For carcinoma in-situ: May increase dose to 80 mg in 50 mL weekly, if tolerated. For prevention of recurrence in patients who have undergone transurethral resection: 50 mg wkly for 4 weeks, followed by 50 mg once a month for 11 months; retain solution in the bladder for 1 hour during each admin.